Trial Profile
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 20 Oct 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 20 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2010 Status changed from recruiting to active, no longer recruiting.